

# Characterization of the $\beta$ -chain N-terminus heterogeneity and the $\alpha$ -chain C-terminus of human platelet GPIIb

## Posttranslational cleavage sites

J.J. Calvete<sup>1,2</sup>, W. Schäfer<sup>1</sup>, A. Henschen<sup>1</sup> and J. González-Rodríguez<sup>2</sup>

<sup>1</sup>Max Planck Institut für Biochemie, D-8033 Martinsried, FRG and <sup>2</sup>Instituto de Química Física, CSIC, Serrano 119, 28006 Madrid, Spain

Received 27 June 1990; revised version received 14 August 1990

Human platelet glycoprotein IIb (GPIIb) and IIIa (GPIIIa) form a  $\text{Ca}^{2+}$ -dependent heterodimer, the integrin GPIIb/IIIa, which functions as the fibrinogen receptor at the surface of activated platelets. GPIIb and GPIIIa are synthesized as single polypeptides from single messages and their amino acid sequences were derived from their cDNAs. The GPIIb precursor is proteolytically processed to yield the known disulphide-bonded two-chain (GPIIb $\alpha$  and GPIIb $\beta$ ) covalent structure found in mature GPIIb. Our present protein chemical and mass spectrometric analyses indicate that the GPIIb precursor is proteolytically cleaved at two or three sites, to give rise to an homogeneous  $\alpha$ -chain (GPIIb 1–856) single disulphide-bonded to one of the two  $\beta$ -chains, which are present in a nearly 1:1 ratio: GPIIb $\beta$ 1 (860–1008), with pyroglutamic acid as its blocked N-terminal residue; and GPIIb $\beta$ 2 (872–1008), with the already known N-terminal sequence. These results satisfy the previously observed electrophoretic size-heterogeneity of the  $\beta$ -chain, confirmed the potential cleavage sites in the junction region, and indicate a probable dual proteolytic processing of GPIIb, which may be relevant to the rest of the two-chain  $\alpha$ -subunits of the integrin family.

Platelet glycoprotein IIb;  $\alpha$ -Chain C-terminus;  $\beta$ -Chain N-terminus heterogeneity; Posttranslational proteolytic processing

## 1. INTRODUCTION

Glycoprotein IIb (GPIIb) of the human platelet plasma membrane is a 136 kDa two-chain bitopic protein [1–3], which together with glycoprotein IIIa (GPIIIa), a 91 kDa bitopic membrane protein [1,2], forms a  $\text{Ca}^{2+}$ -dependent heterodimer [4], the integrin GPIIb/IIIa [5,6], which serves as the receptor for fibrinogen and other adhesive proteins upon platelet activation [7]. The GPIIb precursor gene spans about 17 kb on the long arm of chromosome 17 [8], and contains 30 exons [9]. Biosynthetic studies in human megakaryocyte [10] and HEL cell [11] confirmed the observation that GPIIb is synthesized as a single-chain precursor [12], whose amino acid sequence was cDNA-derived [9,13]. Like other integrin  $\alpha$ -subunits, GPIIb is posttranslationally cleaved after being assembled with GPIIIa in the GPIIb/IIIa heterodimer [11]. In mature GPIIb the heavy-chain (GPIIb $\alpha$ , 114 kDa) is single disulphide-bonded to the light-chain (GPIIb $\beta$ , 22 kDa) between the last cysteine of GPIIb $\alpha$  and the first of

GPIIb $\beta$  [14]. Although the disulphide bond and glycosylation patterns of GPIIb and the C-terminal of GPIIb $\beta$  have already been chemically determined [14–16], the present study on the structural consequences of the posttranslational cleavage of GPIIb was begun to clarify the electrophoretic size-heterogeneity of GPIIb $\beta$  [3] and some apparent discrepancies on the N-terminal sequence of GPIIb $\beta$ . While N-terminal sequence analysis indicated that GPIIb $\beta$  begins at position 872 (LQDPV...) [14,17], Loftus et al. [18] suggested that the GPIIb $\beta$  N-terminus is blocked. They also raised an antiserum against a synthetic peptide analogous to the predicted 859–871 peptide stretch of GPIIb, which recognized GPIIb $\beta$  by immunoelectroblotting analysis. Here we have characterized the C-terminus of the  $\alpha$ -chain and the heterogeneity of the N-terminus of the  $\beta$ -chain, which indicate a probable dual proteolytic processing of GPIIb.

## 2. MATERIALS AND METHODS

### 2.1. Materials

TPCK-trypsin and endoprotease Lys-C were from Sigma and Boehringer-Mannheim, respectively, and the porous glass beads (CPG-10, 200 mesh, 375 Å pore diameter) from Corning. GPIIb and its fully reduced and alkylated chains, CM-GPIIb $\alpha$  and CM-GPIIb $\beta$ , were isolated as previously described [3,19]. The C-terminal 19 kDa CNBr product of cleavage of CM-GPIIb $\alpha$  was prepared as in [14] and isolated by reverse-phase HPLC on a C4 Vydac column (25 ×

Correspondence address: J. González-Rodríguez, Instituto de Química Física, CSIC, Serrano 119, 28006 Madrid, Spain

Abbreviations: GPIIb, GPIIIa, and GPIIb/IIIa, glycoproteins IIb, IIIa, and the heterodimer formed by them, respectively; CM-GPIIb $\alpha$  and CM-GPIIb $\beta$ , the  $\alpha$ - and  $\beta$ -chains of GPIIb, after full reduction and alkylation of GPIIb

0.4 cm, pore size 30  $\mu\text{m}$ , particle size 10  $\mu\text{m}$ ) equilibrated in a mixture of 0.1% trifluoroacetic acid in water (A) and 0.1% trifluoroacetic acid in acetonitrile (B) (90% A/10% B), and eluted at 1 ml/min first isocratically for 5 min, followed by a linear gradient up to 50% B in 90 min.

## 2.2. Methods

Protein assay was done by amino acid analysis on a Biotronik analyzer after hydrolysis at 110°C in 6 N HCl for 24 h. N-terminal sequence analyses were carried out using either a Beckman 890C spinning cup or an Applied Biosystems 470 gas-phase sequencer [20]. Electrophoretic transfer of SDS/PAGE peptide bands into polyvinylidene difluoride membranes was performed following [21].

CM-GPIIb $\beta$  (10 mg/ml) in 50 mM ammonium bicarbonate, 0.1% (v/v) *N*-ethylmorpholine, pH 8.0, was digested with trypsin at an enzyme/substrate ratio 1:100 (w/w) for 18 h at 37°C. The 19 kDa CNBr product of GPIIb $\alpha$  (5 mg/ml) in 0.1 M Tris-HCl, pH 8.6, was digested with endoprotease Lys-C at an enzyme/peptide ratio 1:25 (w/w) for 24 h at 37°C. Both tryptic and endoLys-C digestion products were isolated by reverse-phase HPLC, as indicated above.

Peptide C-terminal sequence determination was carried out according to [22] with minor modifications described in [16]. Mass spectra were recorded with a mass spectrometer HSQ 30 (Finnigan MAT, Bremen) equipped with an atom gun (Ion Tech. Ltd., Teddington, UK). Peptides were dissolved in acetonitrile/acetic acid/water (50:10:40 v/v) and mixed with glycerol [23].

## 3. RESULTS AND DISCUSSION

### 3.1. The GPIIb $\beta$ N-terminal heterogeneity

To find out the structural bases of the size-heterogeneity of the  $\beta$ -chain of GPIIb, CM-GPIIb $\beta$  was subjected to SDS/12% polyacrylamide gel electrophoresis (Fig. 1) where it splits in two separate bands, about 40% of  $\beta$ 1, the larger, and 60% of  $\beta$ 2, as determined by densitometry. These bands were subsequently electroblotted into polyvinylidene difluoride membranes and subjected to gas-phase N-terminal sequence analysis, where  $\beta$ 2 yielded the already chemically determined N-terminal sequence of GPIIb $\beta$  (872 LQDPV...), whereas the  $\beta$ 1 N-terminus was found blocked. To determine this blocked N-terminus, CM-GPIIb $\beta$  was digested with trypsin and the tryptic products, after separation by reverse-phase HPLC (Fig. 2), were identified by N-terminal sequence and amino acid analyses. All the obtained fractions had sequenceable material, except for fraction 2, whose amino acid analysis clearly let us assign it to the peptide stretch 860 QIFLPEPEQPSR 871 in the predicted sequence of GPIIb [13]. Mass spectrometric analysis of fraction 2 (Fig. 3), besides confirming this assignment, also showed that the blocked N-terminus of GPIIb $\beta$ 1 is a pyroglutamic acid residue ( $M + H^+$  calculated 1422.6, found 1422.9). These results explain the previously found heterogeneity of GPIIb $\beta$  [3] and confirm the suggestion that the N-terminus of GPIIb $\beta$  is readily blocked [18]. However, our data differ quantitatively from those of Loftus et al. [18]. While they estimated that  $\beta$ 2 represents as little as 3% of mature GPIIb $\beta$ , we have always found a  $\beta$ 1/ $\beta$ 2 ratio of nearly 1:1 in our preparations from outdated platelet concentrates. Further experiments will have to be designed to ascertain




Fig. 1. Analysis of the size-heterogeneity of the fully reduced and alkylated  $\beta$  chain of GPIIb by SDS-12% polyacrylamide gel electrophoresis and Coomassie blue staining. The blocked N-terminus of the  $\beta$ 1 chain and the chemically determined N-terminal sequence of the  $\beta$ 2 chain are indicated on the right-hand side.

whether  $\beta$ 2 is formed at the same stage as  $\beta$ 1, or whether it is formed at later stages during thrombogenesis, in the blood stream or during blood bank storage.




Fig. 2. Isolation by reverse-phase HPLC of the tryptic peptide carrying the blocked N-terminal sequence of GPIIb $\beta$ 1. The tryptic products of digestion of CM-GPIIb $\beta$  were isolated on a C4 Vydac column equilibrated in a mixture of 0.1% trifluoroacetic acid in water (v/v) (A) and 0.1% trifluoroacetic acid in acetonitrile (B) (90% A/10% B) and eluted at 1 ml/min, first isocratically for 5 min, followed by a linear gradient up to 70% of B in 60 min. The chemically determined N-terminal sequence for each fraction is indicated, except that for fraction 2, which contains the peptide carrying the blocked N-terminus of the  $\beta$ 1 chain.





Fig. 3. Fast atom bombardment mass spectrometry of the tryptic peptide of CM-GPIIb $\beta$  from fraction 2 in Fig. 2, which confirms the chemically determined sequence of this peptide ( $\beta$ 1 860–871) and identifies the blocked N-terminus of GPIIb $\beta$ 1 as a pyroglutamic acid residue.

### 3.2. The localization of the C-terminus of GPIIb $\alpha$

The above results raised the question of the actual location of the C-terminus of GPIIb $\alpha$  within the GPIIb precursor sequence [9,13]. When CM-GPIIb $\alpha$  was digested with trypsin, and the tryptic products were isolated by reverse-phase HPLC (not shown) and subjected to amino acid and N-terminal sequence analyses, all the possible peptides around the  $\alpha$ - $\beta$  chain junction were obtained, except those upstream Lys-855, which



**Fig. 4. Chemical determination of the C-terminal sequence of the GPIIb $\alpha$  chain.** HPLC analysis of the thiohydantoin-amino acid derivatives from the first two cycles of C-terminal sequential degradation of the C-terminal 19 kDa CNBr-product of cleavage of CM-GPIIb $\alpha$ , as described in section 2.2. Peaks are labelled using the one-letter symbols.

let us deduce that the  $\alpha$  chain C-terminus must be somewhere between Lys-855 and Arg-859, because residues upstream Arg-859 are already found in the  $\beta 1$  chain. To locate the exact position of this C-terminus, the C-terminal 19 kDa CNBr-product of cleavage of CM-GPIIb $\alpha$  was prepared and isolated, and its C-terminal sequence chemically determined, as described in section 2.2. Two degradation cycles were successfully performed (Fig. 4), which allowed us to identify Lys-855 and Arg-856 as the last two residues of GPIIb $\alpha$ , and to locate a third proteolytic cleavage site, besides the two already found (Fig. 5).

Our results confirm the current hypothesis [24–27] that the occurrence of integrin two-chain or single-chain  $\alpha$  subunits is related with the conservation of the sequence of the heavy–light chain junction region (between residues 855 and 871 in the cDNA-derived GPIIb sequence), which contains the two consensus pairs of basic residues and the single basic residue preceded by a number of prolines and acid residues, which determine the presence of the three proteolytic cleavage sites. The abnormal GPIIb found by Jung et al. [28] in the platelets of a thrombasthenic patient, which does




Fig. 5. Localization of the three proteolytic sites in the cDNA-derived amino acid sequence of the light-heavy chain junction region in the GPIIb precursor [13], together with the C-terminal sequence of GPIIb $\alpha$  and the two N-terminal sequences of GPIIb $\beta$  ( $\beta$ 1 and  $\beta$ 2). S-S represents the single interchain disulphide bond [3], and Z in  $\beta$ 1 is the symbol for pyroglutamic acid.

not release the  $\beta$  chain upon reduction, could be related to a lack or anomaly in exon 26, which codes for the  $\alpha$ - $\beta$  chain junction region, although other genetic defects must be involved, because this abnormal GPIIb does not assemble in the GPIIb/IIIa heterodimer, which occurs at an earlier stage in the biosynthesis than the proteolytic processing [11]. Finally, Bray et al. [29] have suggested that the size-heterogeneity of GPIIb $\beta$  that we found [3] could be due to the splicing out of exon 28, corresponding to 34 amino acids of the extracellular domain of GPIIb $\beta$ , among them ASN 60 (in  $\beta$ 2): the single glycosylation point of GPIIb $\beta$  [15]. This does not seem to be the case, because both  $\beta$ 1 and  $\beta$ 2 are glycosylated, and therefore, none of them can be the products of the transcript due to the splicing out of exon 28.

**Acknowledgements:** Dr G.A. Rivas is gratefully acknowledged for his help in the preparation of GPIIb, CM-GPIIb $\alpha$  and CM-GPIIb $\beta$ . We also want to thank Dr D. Georgopoulous for helping with the amino acid analyses, Mrs G. Pinillos, Mrs H. Gross, Mrs B. Rinke, and Miss A. Vacas for technical assistance, Miss S. Salado for typing the manuscript, and the Blood Banks of Centro Ramón y Cajal, La Paz and Doce de Octubre (Madrid) for providing us with outdated platelet concentrates. This work was supported by the DGICYT (PB 86-0629 and PM 88-0022) and an Acción Integrada Hispano-Alemana (1989-1990 43A).

## REFERENCES

- [1] Nurden, A.T., George, J.N. and Phillips, D.R. (1986) in: *Biochemistry of Platelets* (Phillips, D.R. and Shuman, M.A. eds) pp. 159-224, Academic Press, New York.
- [2] Usobiaga, P., Calvete, J.J., Saiz, J.L., Eirin, M.T. and González-Rodríguez, J. (1987) *Eur. Biophys. J.* 14, 211-218.
- [3] Calvete, J.J. and González-Rodríguez, J. (1986) *Biochem. J.* 240, 155-161.
- [4] Kunicki, T.J., Pidard, D., Rosa, J.-P. and Nurden, A.T. (1981) *Blood* 58, 268-278.
- [5] Hynes, R.O. (1987) *Cell* 48, 549-554.
- [6] Phillips, D.R., Charo, I.F., Parise, L.V. and Fitzgerald, L.A. (1988) *Blood* 71, 831-843.
- [7] Marguerie, G.A., Ginsberg, M.H. and Plow, E.F. (1987) in: *Platelets in Biology and Pathology*, vol. 3 (MacIntyre, D.E. and Gordon, J.L. eds) pp. 95-125, Elsevier, Amsterdam.
- [8] Bray, P.F., Rosa, J.-P., Johnston, G.I., Shiu, D.T., Cook, R.G., Lau, C., Kan, Y.W., McEver, R.P. and Shuman, M.A. (1987) *J. Clin. Invest.* 80, 1812-1817.
- [9] Heidenreich, R., Eisman, R., Surrey, S., Delgrosso, K., Bennett, J.S., Schwartz, E. and Poncz, M. (1990) *Biochemistry* 29, 1232-1244.
- [10] Duperray, A., Berthier, R., Chagnon, E., Ryckewaert, J.-J., Ginsberg, M.H., Plow, E.F. and Marguerie, G. (1987) *J. Cell Biol.* 104, 1665-1673.
- [11] Rosa, J.-P. and McEver, R.P. (1989) *J. Biol. Chem.* 264, 12596-12603.
- [12] Bray, P.F., Rosa, J.-P., Lingappa, V.R., Kan, Y.W., McEver, R.P. and Shuman, M.A. (1986) *Proc. Natl. Acad. Sci. USA* 83, 1480-1484.
- [13] Poncz, M., Eisman, R., Heidenreich, R., Silver, S.M., Vilaire, G., Surrey, S., Schwartz, E. and Bennett, J.S. (1987) *J. Biol. Chem.* 262, 8476-8482.
- [14] Calvete, J.J., Rivas, G., Alvarez, M.V., Hew, C.-L., Henschen, A. and González-Rodríguez, J. (1989) *Biochem. J.* 261, 551-560.
- [15] Calvete, J.J., Henschen, A. and González-Rodríguez, J. (1989) *Biochem. J.* 261, 561-568.
- [16] Calvete, J.J., Schäfer, W., Henschen, A. and González-Rodríguez, J. (1990) *FEBS Lett.* 263, 43-46.
- [17] Charo, I.F., Fitzgerald, L.A., Steiner, B., Rall, Jr., S.C., Bekeart, L.S. and Phillips, D.R. (1986) *Proc. Natl. Acad. Sci. USA* 83, 8351-8355.
- [18] Loftus, J.C., Plow, E.F., Jennings, L.K. and Ginsberg, M.H. (1988) *J. Biol. Chem.* 263, 11025-11028.
- [19] Eirin, M.T., Calvete, J.J. and González-Rodríguez, J. (1986) *Biochem. J.* 240, 147-153.
- [20] Edman, P. and Henschen, A. (1975) in: *Protein Sequence Determination* (Needleman, S.B. ed.) pp. 232-279, Springer, Berlin.
- [21] Madsudaira, P. (1987) *J. Biol. Chem.* 262, 10035-10038.
- [22] Hawke, D.H., Lahm, H.W., Shively, J.E. and Todd, R.W. (1987) *Anal. Biochem.* 166, 298-307.
- [23] Naylor, S., Finders, A.F., Gibson, B.M. and Williams, D.H. (1986) *J. Am. Chem. Soc.* 108, 6359-6363.
- [24] Argraves, W.S., Suzuki, S., Arai, H., Thompson, K., Pierschbacher, M.D. and Ruoslahti, E. (1987) *J. Cell Biol.* 105, 1183-1190.
- [25] Suzuki, S., Argraves, W.S., Arai, H., Languino, L.R., Pierschbacher, M. and Ruoslahti, E. (1987) *J. Biol. Chem.* 262, 14080-14085.
- [26] Corbi, A., Kishimoto, T.K., Miller, L.J. and Springer, T.A. (1988) *J. Biol. Chem.* 263, 12403-12411.
- [27] Takada, Y. and Hemler, M.E. (1989) *J. Cell Biol.* 109, 397-407.
- [28] Jung, S.M., Yoshida, N., Aoki, N., Tanoue, K., Yamazaki, H. and Moroi, M. (1988) *Blood* 71, 915-922.
- [29] Bray, P.F., Leung, C.S.-I. and Shuman, M.A. (1990) *J. Biol. Chem.* 265, 9587-9590.